Overview

A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2027-06-18

Target enrollment:

Participant gender:

Summary

This Phase I study aims to evaluate the safety, tolerability and PK of JSB462 in Japanese patients with metastatic prostate cancer.

Phase:

PHASE1

Details

Lead Sponsor:

Novartis Pharmaceuticals